MBX-8025 regulatory update

FDA granted Orphan Drug designation to MBX-8025 from CymaBay to treat Type I and V hyperlipoproteinemia. The PPAR delta agonist completed a Phase II trial in patients with mixed dyslipidemia, with a ...